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Crowley et al 311Methods: Safety findings are reported for 0 to$156 weeks from the Efficacy and Safety Trial Evaluating the
Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2.Results: The 0 to $156eweek apremilast-exposure period included 1184 patients treated twice daily with
apremilast 30 mg (1902.2 patient-years). During 0 to #52 weeks, the adverse events (AEs) that occurred in
$5% of patients included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension
headache, and headache. From 0 to $156 weeks, no new AEs (affecting $5% of the population) were
reported. AEs, serious AEs, and study drug discontinuations caused by AEs did not increase with long-term
exposure. During the 0 to $156eweek period, the rates of major cardiac events (exposure-adjusted
incidence rate [EAIR] 0.5/100 patient-years), malignancies (EAIR 1.2/100 patient-years), depression (EAIR
1.8/100 patient-years), or suicide attempts (EAIR 0.1/100 patient-years) did not increase in comparison with
the rates found during the 0 to #52eweek period. No serious opportunistic infections, reactivation of
tuberculosis, or clinically meaningful effects on laboratory measurements were reported.Limitations: This study had a high dropout rate (21% of patients ongoing [156 weeks); most were
unrelated to safety concerns.Conclusions: Apremilast demonstrated an acceptable safety profile and was generally well tolerated for
$156 weeks. ( J Am Acad Dermatol 2017;77:310-7.)
Key words: apremilast; clinical trial; ESTEEM; phosphodiesterase 4 inhibitor; psoriasis; psoriatic arthritis;
safety.CAPSULE SUMMARY
d Efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and
psoriatic arthritis have been previously
reported up to 52 weeks.
d We report long-term (3-year) safety of
apremilast in patients with psoriasis.
d This information supports the favorable
benefit-risk profile of apremilast for
patients with psoriasis requiring long-
term systemic therapy.Psoriasis is a chronic, sys-
temic inflammatory disease
that affects 1%-3% of
the world population and
requires long-term manage-
ment with agents that are
both effective and safe.1-3
Available therapies are often
compromised by safety and
tolerability issues, route of
administration (injection or
infusion vs oral), and the
inconvenience of frequent
laboratory testing and regu-
lar office visits for monitoring
patients during treatment.4-6Safety of psoriasis treatments is particularly
important in light of rates of comorbidities among
patients with psoriasis, including history of major
depression (16.5%), diabetes mellitus (16.5%),
coronary artery disease (8.4%), and myocardial
infarction (7.5%).7
Apremilast, approved in both the United States
and Europe for the treatment of psoriasis and
psoriatic arthritis, is an oral phosphodiesterase 4
(PDE4) inhibitor that works within immune cells to
regulate inflammatory mediators.8 The Efficacy and
Safety Trial Evaluating the Effects of Apremilast in
Psoriasis (ESTEEM) phase 3 clinical trial program
consisted of 2 randomized, placebo-controlled
studies evaluating efficacy, safety, and tolerability
of apremilast for the treatment of moderate-to-severe
plaque psoriasis. Apremilast significantly reducedsigns and symptoms and had
an acceptable safety profile
through week 52.9,10
Apremilast also improves
nail, scalp, and palmoplantar
psoriasis; pruritus and skin
discomfort; and psoriatic
arthritis.11-15 Longer-term
safety of apremilast has not
yet been reported. We there-
fore assessed the overall
safety and tolerability of
apremilast 30 mg twice daily
for $156 weeks (data as of
February 14, 2015) in a
pooled analysis of patientswith moderate-to-severe psoriasis in ESTEEM 1
(NCT01194219) and ESTEEM 2 (NCT01232283).METHODS
Study design
ESTEEM 1 and ESTEEM 2 were similarly designed
phase 3, multicenter, randomized, double-blind,
placebo-controlled studies. Full details of the study
designs have been previously reported.9,10 At the
end of the week 52 visit, patients were eligible to
continue apremilast for up to 4 additional years.
Patients provided written informed consent before
study-related procedures were performed, and the
protocols and consent were approved by institu-
tional review boards or ethics committees at all
investigational sites. The studies were conducted in
Abbreviations used:
AE: adverse event
EAIR: exposure-adjusted incidence rate
ESTEEM: Efficacy and Safety Trial Evaluating the
Effects of Apremilast in Psoriasis
GI: gastrointestinal
PDE4: phosphodiesterase 4
TB: tuberculosis
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Patients
Both studies enrolled adults aged $18 years with
moderate-to-severe plaque psoriasis who were
candidates for phototherapy or systemic therapy.
Key exclusion criteria included other clinically sig-
nificant or major uncontrolled disease, significant
infection, and active or history of incompletely
treated tuberculosis (TB).
Safety analysis
Safety assessments involved collection of data on
adverse events (AEs), clinical laboratory tests, phys-
ical examination, and vital signs at each visit and
were analyzed among the safety population (all
randomized patients who received $1 dose of study
medication). Safety outcomes were summarized
descriptively. Exposure-adjusted incidence rates
(EAIR) were used to assess major cardiac events,
malignancies, and serious infections. EAIR per 100
patient-years is defined as 100 times the number of
patients (n) reporting the event divided by patient-
years (up to the first event start date for each patient
reporting the event).
RESULTS
Patients
The pooled ESTEEM safety population included
1250 patients (week 0 patients treated with pla-
cebo [n = 418] or apremilast [n = 832]). A total of
1184 patients were treated with apremilast begin-
ning at week 0 or week 16 and 249 patients
(21.0%) received apremilast for $156 weeks. The
most common reasons for study discontinuation
during 0 to $156 weeks were lack of efficacy
(34.7%) and withdrawal by patient (18.8%); 11.2%
of patients discontinued because of AEs. Other
reasons (each\10.0%) included loss to follow-up,
noncompliance with study drug, protocol viola-
tion, other, and death. Patients in the safety pop-
ulation were comparable across treatment arms
(Table I). Most (89.9%) had a history of $1
comorbid illness at baseline. Of note, [50% ofpatients were defined as clinically obese (baseline
body mass index $30 kg/m2).
There was no requirement for latent TB testing
before enrollment. Patients with active TB or a
history of incompletely treated TB were excluded.
Seven (0.6%) patients previously treated for TB were
enrolled in the ESTEEM trials. Their medical histories
included latent TB (n = 4), pulmonary TB (n = 1),
disseminated TB (n = 1), and TB (n = 1). Of these, 1
patient received placebo, and 1 patient with dissem-
inated TB received placebo with subsequent apre-
milast. The remaining 5 patients received apremilast
from baseline.
Overview of adverse events
The most common AEs were diarrhea, nausea,
upper respiratory tract infection, nasopharyngitis,
tension headache, and headache (Table II). Rates for
overall AEs and most common AEs (particularly
diarrhea and nausea) decreased over time. Most
cases of diarrhea and nausea were mild-to-
moderate in severity, occurred most frequently
during the first 2 weeks of apremilast treatment,
and generally resolved within 4 weeks.
Rates of serious AEs were comparable across
exposure periods (0 to #52 weeks, [52 to
#104 weeks, [104 to #156 weeks, and 0 to
$156 weeks) and did not increase with long-term
apremilast exposure. Serious AEs occurring in $2
patients in any exposure period (0 to $156 weeks)
included coronary artery disease (n = 6), acute
myocardial infarction (n = 4), osteoarthritis (n = 4),
and nephrolithiasis (n = 4). Discontinuations for
AEs were few (\2% for any AE) and occurred
primarily during the first few weeks of treatment. A
total of 3 deaths occurred in patients receiving
apremilast (1 during each year of exposure; Table
II), due to cardiac failure, cerebrovascular accident,
and severe mitral stenosis with congestive heart
failure.
Adverse events of interest
Major cardiac events were uncommon and
occurred at similar EAIRs across the 0 to #52eweek
and 0 to $156eweek apremilast-exposure periods
(0.4/100 patient-years and 0.5/100 patient-years,
respectively; Table III). EAIRs for malignancies were
1.6/100 patient-years and 1.2/100 patient-years in the
0 to #52eweek and 0 to $156eweek apremilast-
exposure periods, respectively; these included non-
melanoma skin cancers. Incidence of basal cell
carcinoma was greater than that of squamous cell
carcinoma, similar to what is expected in the general
population.16 EAIRs for serious infections were
0.5/100 patient-years and 0.9/100 patient-years
Table I. Baseline demographics and clinical characteristics of patients from ESTEEM 1 and 2*
Characteristic Placebo n = 418 Apremilast 30 mg bid n = 832* Totaly N = 1184*
Age, mean (SD), years 46.3 (12.9) 45.6 (13.1) 45.9 (13.0)
Male, n (%) 294 (70.3) 553 (66.5) 805 (68.0)
White, n (%) 377 (90.2) 753 (90.5) 1071 (90.5)
Weight, mean (SD), kg 92.7 (23.0) 92.5 (21.9) 92.3 (21.8)
Body mass index, mean (SD), kg/m2 31.1 (7.3) 31.1 (6.7) 31.0 (6.7)
Psoriasis duration, mean (SD), years 18.7 (12.3) 19.2 (12.6) 19.1 (12.5)
History of psoriatic arthritis, n (%) 63 (15.1) 164 (19.7) 215 (18.2)
Prior use of psoriasis medications
Phototherapy, n (%) 118 (28.2) 257 (30.9) 361 (30.5)
Conventional systemic therapy, n (%) 154 (36.8) 315 (37.9) 443 (37.4)
Biologic therapy, n (%) 124 (29.7) 251 (30.2) 345 (29.1)
Comorbidities, n (%)
Hypertension 134 (32.1) 257 (30.9) 376 (31.8)
Obesityz 61 (14.6) 130 (15.6) 182 (15.4)
Depression 56 (13.4) 114 (13.7) 155 (13.1)
Hyperlipidemia 53 (12.7) 105 (12.6) 156 (13.2)
Type 2 diabetes 39 (9.3) 87 (10.5) 122 (10.3)
Bid, Twice a day; BMI, body mass index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; SD, standard
deviation.
*N indicates the total number of apremilast patients as treated, and n indicates the number of patients initially treated at week 0; actual
number of patients at each end point varies.
yIn total, 1184 patients were treated with apremilast beginning at week 0 or week 16. A total of 249 patients (21.0%) received apremilast for
$156 weeks.
zPatients with obesity who reported awareness of their obesity or had a prior clinical diagnosis of obesity from a health care professional.
Obesity was not defined as a BMI of $30 kg/m2.
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apremilast-exposure periods, respectively; these in-
cluded urinary tract infection (n = 2), appendicitis
(n = 3), and pneumonia (n = 2; Table III). No case of
serious opportunistic infection, including clinical
reactivation of TB, was reported with long-term
apremilast exposure, despite inclusion of 7 patients
with medical histories of TB.
At baseline, 178 (14.2%) patients reported a
history of depression, and 156 (12.4%) were
taking an antidepressant medication. During the
placebo-controlled phase, patient-reported depres-
sion (ie, as spontaneously reported by patients and
not a clinical diagnosis by a health care professional)
occurred in 1.4% (12/832) of patients treated with
apremilast versus 0.5% (2/418) of those receiving
placebo. AEs of depression with apremilast treat-
ment did not increase over time, with depression
reported in 24 (2.0%; EAIR 2.7/100 patient-years)
patients during the 0 to#52eweek period and in 33
(2.8%; EAIR 1.8/100 patient-years) patients during
the 0 to $156eweek period. There was 1 suicide
attempt with apremilast treatment (0 to#52 weeks),
and no completed suicides in patients treated with
apremilast. One patient receiving placebo in
ESTEEM 1 committed suicide.Weight change
Over the 0 to $156eweek apremilast-exposure
period, mean percent change from baseline body
weight was 1.53 (Fig 1, A). Most patients taking
apremilast for $156 weeks maintained body weight
within 5% of baseline weight; 21.9% of patients lost
[5% of their baseline body weight. The proportion
of patients reporting weight loss tended to be higher
among patients with higher baseline body mass
index; this weight loss occurred primarily in the first
year of apremilast treatment (Fig 1, B). The weight
loss did not lead to any overt medical sequelae. Two
(0.2%) patients discontinued treatment due toweight
decrease. Analysis of the relationship between
gastrointestinal (GI) AEs and weight loss in
apremilast-treated patients revealed no association
between weight loss and diarrhea, nausea, or
vomiting.10
Laboratory parameters
Marked abnormalities and shifts outside of the
normal range in clinical chemistry and hematology
laboratory parameters were infrequent, reversible,
and comparable across treatment groups. No
clinically meaningful effects on renal function
parameters were reported for 0 to $156 weeks.
Table II. Overview of adverse events in ESTEEM 1 and 2
Patients
Apremilast-exposure period*
0 to #52 weeks [52 to #104 weeks [104 to #156 weeks 0 to $156 weeks
Apremilast 30 mg bid
n = 1184; pt-yrs = 915.7
Apremilast 30 mg bid
n = 654; pt-yrs = 514.6
Apremilast 30 mg bid
n = 401; pt-yrs = 339.0
Apremilast 30 mg bid
n = 1184; pt-yrs = 1902.2
n (%) EAIR/100 pt-yrs n (%) n (%) n (%) EAIR/100 pt-yrs
$1 AE 939 (79.3) 316.9 380 (58.1) 230 (57.4) 985 (83.2) 237.5
$1 severe AE 86 (7.3) 9.7 33 (5.0) 17 (4.2) 126 (10.6) 7.0
$1 serious AE 58 (4.9) 6.4 36 (5.5) 18 (4.5) 106 (9.0) 5.9
AE leading to drug
withdrawal
93 (7.9) 10.2 20 (3.1) 14 (3.5) 132 (11.1) 7.0
Any AE leading to deathy 1z (0.1) 0.1 1x (0.2) 1ǁ (0.2) 3 (0.3) 0.2
AEs occurring in[5% of patients, n (%)
Diarrhea 205 (17.3) 15 (2.3) 7 (1.7) 221 (18.7)
Nausea 186 (15.7) 5 (0.8) 6 (1.5) 195 (16.5)
URTI 184 (15.5) 58 (8.9) 27 (6.7) 227 (19.2)
Nasopharyngitis 167 (14.1) 43 (6.6) 24 (6.0) 196 (16.6)
Tension headache 106 (9.0) 8 (1.2) 5 (1.2) 115 (9.7)
Headache 75 (6.3) 6 (0.9) 7 (1.7) 86 (7.3)
AE, Adverse event; bid, twice daily; EAIR, exposure-adjusted incidence rate; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of
Apremilast in Psoriasis; pt-yrs, patient-years; URTI, upper respiratory tract infection.
*The data on apremilast-exposure periods (0 to #52 weeks,[52 to #104 weeks,[104 to #156 weeks, and 0 to $156 weeks [ie, beyond
3 years]) included all patients who received apremilast, regardless of when apremilast use started (week 0 or week 16).
yA 51-year-old white female patient died on day 354 from an intracranial hemorrhage, 130 days after her last dose of apremilast while in
period C (weeks 32-52). This patient was considered to not be on apremilast at the time of death because of the long length of time she was
off treatment, and so, this is not included herein.
zA 30-year-old woman with a history of depression and obesity had a fatal cardiac failure on day 111.
xA 69-year-old man with a history of diabetes, hypertension, and hyperlipidemia had a fatal cerebrovascular accident on day 666 of
apremilast exposure.
ǁA 57-year-old woman with a history of congestive heart failure, hypertension, and coronary artery disease died of severe mitral stenosis
with congestive heart failure on day 979 of apremilast exposure. EAIR per 100 patient-years is defined as 100 times the number of patients
(n) reporting the event divided by patient-years (up to the first event start date for each patient reporting the event). EAIR cannot be
calculated for exposure durations that do not start at week 0.
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Analysis of data pooled from ESTEEM 1 and 2
allowed for a thorough characterization of
apremilast safety for [3 years in patients with
moderate-to-severe plaque psoriasis, many of
whom had comorbid conditions typical of the
general psoriasis patient population, including
hypertension, obesity, and depression.1
In the ESTEEM studies, most AEs were mild or
moderate in severity and did not lead to treatment
discontinuation. Rates of AEs reported with
apremilast treatment decreased with longer-term
([52 weeks) exposure. Diarrhea and nausea, which
are among the most common AEs associated with
oral PDE4 inhibitors,17 were predominantly mild or
moderate in severity, occurred early, and resolved
within the first month. Diarrhea induced by PDE4
inhibitors is thought to be secretory. PDE4 inhibition
increases intracellular levels of cyclic adenosine
monophosphate, which in turn activates chloride
channels in small-bowel crypts, resulting in chlorideion secretion.18 Caffeine causes diarrhea by a similar
mechanism.19
The nausea and vomiting induced by PDE4
inhibition is believed to arise from peripheral and
central mechanisms.20,21 Counseling patients and
setting expectations before treatment initiationmight
increase the likelihood of treatment success, and
having patients take apremilast with food could help
reduce the nausea. If GI AEs require intervention, a
number of nonpharmacologic and pharmacologic
measures are available to manage these symptoms in
the short-term, with the goal of optimizing long-term
treatment outcomes. The few patients who required
treatment for GI AEs in ESTEEM most commonly
used loperamide or bismuth subsalicylate for
diarrhea and ondansetron or prochlorperazine for
nausea.22
Incidences of major cardiac events, malignancies,
and depression did not increase with long-term
apremilast exposure based on EAIR. Rates of serious
infections remained low with long-term apremilast
Table III. Adverse events of interest in ESTEEM 1 and 2
Patients
Apremilast-exposure period*
0 to #52 weeks 0 to $156 weeks
Apremilast 30 mg bid
n = 1184; pt-yrs = 915.7
Apremilast 30 mg bid
n = 1184; pt-yrs = 1902.2
n (%) EAIR/100 pt-yrs n (%) EAIR/100 pt-yrs
Major cardiac events 4 (0.3) 0.4 10 (0.8) 0.5
Malignanciesy 15 (1.3) 1.6 23 (1.9) 1.2
Serious infections 5 (0.4) 0.5 17 (1.4) 0.9
Serious opportunistic infection 0 (0) 0 0 (0) 0
Psychiatric serious AEs
Depression 1 (0.1) 0.1 2 (0.2) 0.1
Suicide attempts 1 (0.1) 0.1 1 (0.1) 0.1
EAIR per 100 patient-years is defined as 100 times the number of patients (n) reporting the event divided by patient-years (up to the first
event start date for each patient reporting the event). EAIR cannot be calculated for exposure durations that do not start at week 0.
AE, Adverse event; bid, twice a day; EAIR, exposure-adjusted incidence rate; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of
Apremilast in Psoriasis; pt-yrs, patient-years.
*The apremilast-exposure periods (0 to #52 weeks,[52 to #104 weeks,[104 to #156 weeks, and 0 to $156 weeks [ie, beyond 3 years]
include all patients who received apremilast regardless of when apremilast exposure started [week 0 or week 16]). Apremilast exposure is
defined as the total amount of time each patient used apremilast, which includes the day of the first dose and the day of the last dose of
apremilast.
yIncluding nonmelanoma skin cancer.
Fig 1. A, Percentage of weight change from baseline over time. B, Percentage of patients
exhibiting [5% weight loss by apremilast-exposure period (0 to #52 weeks and 0 to
$156 weeks). C, Percentage of patients exhibiting[5% weight loss from baseline by body
mass index category (overall,\25,$25 to\30, and $30). EOP, End of phase; n/m, number of
patients with weight change divided by number of patients with sufficient data. *m includes all
patients who received apremilast 30 mg twice daily regardless of when apremilast exposure
started (week 0 or week 16). Represents all patients who experienced weight loss at anytime
during the study; some patients experienced weight loss during both study periods.
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serious opportunistic infections or reactivations of
TB infection and no clinically meaningful changes in
laboratory measurements. Routine laboratory
monitoring is not required during apremilast
treatment, as indicated by the label.23
A warning for depression is included on the
apremilast label because an imbalance in AEs (as
spontaneously reported by patients) was noted at
week 16. However, the incidence of depression didnot increase with longer apremilast use. One patient
receiving placebo committed suicide whereas no
suicides were completedwith patients on apremilast;
one patient on apremilast attempted suicide. The
rate of depression as an AE with apremilast is lower
than the background rate in the psoriasis population
($10%), as noted in recent reviews.24,25
Incidences of major cardiac events, malignancies,
and infections observed with apremilast were
within ranges expected for the psoriasis patient
J AM ACAD DERMATOL
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reports, including the international Psoriasis
Longitudinal Assessment and Registry database
6-year analysis26,27 and the US claims database
5-year analysis28 (Supplemental Table I, available at
http://jaad.org). These long-term safety analyses
included patients with psoriasis receiving long-term
treatment with nonbiologic systemic therapies,
biologics, or phototherapy.28 The lack of impact of
apremilast on blood cell counts, serious
opportunistic infections, serious infections, and
malignancies suggests that apremilast does not
appear to have immunosuppressive effects such as
those associated with cyclosporine or tofacitinib.29,30
An important limitation of our study was a
relatively high dropout rate (21% of patients were
still ongoing at the 182-week data cutoff). Because
only 11.2% of patients discontinued because of AEs,
the high dropout rate does not appear to be driven
by safety concerns.
Conclusions
Apremilast, an oral PDE4 inhibitor, demonstrated
an acceptable safety profile and was generally well
tolerated for $156 weeks. No new safety concerns
were identified with long-term exposure in
this psoriasis patient population with several
comorbidities. The benefit-risk profile of apremilast,
including the oral route of administration, lack of
laboratory monitoring requirements during treat-
ment, and lack of cumulative, specific organ toxicity,
makes apremilast an attractive option for patients
with psoriasis requiring long-term systemic therapy.
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Supplemental Table I. AEs of interest across long-
term psoriasis studies
AE of interest
PSOLAR 6-year
analysis,S1 rate
per 100 patient-years*
US claims 5-year
analysis,S2 rate
per 100 patient-years*
MACE, total 0.36
Infliximab 0.38
Ustekinumab 0.33
Other biologics 0.33
Nonbiologics 0.45
Malignancies (excluding
NMSC), total
0.68 1.42
Infliximab 0.58 2.30
Ustekinumab 0.53
Other biologics 0.74 0.78-1.14
Nonbiologics 0.81 1.53
Serious infection, total 1.50
Infliximab 2.73 5.21
Ustekinumab 1.00
Other biologics 1.80 2.88-3.25
Nonbiologics 1.26 3.32
AE, Adverse event; MACE, major adverse cardiovascular events;
NMSC, nonmelanoma skin cancer; PSOLAR, Psoriasis Longitudinal
Assessment and Registry.
*These events (reported as per 100 patient-years) were calculated
by using different methods than those used to calculate the
exposure-adjusted incidence rate per 100 patient-years.
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